Artifact

Vioxx

Merck's painkiller (rofecoxib), withdrawn worldwide on 30 September 2004.

5 links, 2 backed by primary records

Connections 5

Report of the VIGOR trial of Vioxx, 2000 the drug tested against naproxen Scholarship & press 4

Proof 4 sources

Merck Settles Vioxx Lawsuits for $4.85 Billion Without Admitting Fault (AP, via Insurance Journal), The Associated Press, via Insurance Journal, 12 Nov 2007. Scholarship & press
Merck pulled Vioxx from the market Sept. 30, 2004 after its researchers determined the then-blockbuster painkiller doubled risk of heart attacks and strokes.
Merck & Co. said last Friday it will pay $4.85 billion to end thousands of lawsuits over its painkiller Vioxx in what is believed to be the largest drug settlement ever.
Testimony of David J. Graham, MD, MPH, November 18, 2004, U.S. Senate Committee on Finance, 18 Nov 2004. Primary record Archived copy
Good morning. My name is David Graham, and I am pleased to come before you today to speak about Vioxx, heart attacks and the FDA.
Vioxx (rofecoxib), U.S. Food and Drug Administration, 30 Sep 2004. Primary record
Vioxx is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999
Expression of Concern: Bombardier et al., "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis," N Engl J Med 2000;343:1520-8, The New England Journal of Medicine, 29 Dec 2005. Scholarship & press
The VIGOR study was designed primarily to compare gastrointestinal events in patients with rheumatoid arthritis randomly assigned to treatment with rofecoxib (Vioxx) or naproxen (Naprosyn), but data on cardiovascular events were also monitored.

Page history 1 change